Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical pharmacology in drug development

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cpdd.147PMID 27140799
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers

  2013cited by this paper
• Biology of human sodium glucose transporters.

  2011cited by this paper
• Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion

  2011cited by this paper
• The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.

  2010cited by this paper
• The expanding clinical spectrum of Anderson–Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy

  2004cited by this paper
• Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy

  2003cited by this paper
• A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.

  2003cited by this paper
• In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives.

  2000cited by this paper
• Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor

  1999cited by this paper
• The metabolic and molecular bases of inherited disease: Vols I, II and III (7th edn): edited by Charles R. Scriver, Arthur L. Beaudet, William S. Sly and David Valle McGraw-Hill, 1995, £195.00 hbk (4605 pages) ISBN 0 07 909826 6

  1996cited by this paper
• Transit of pharmaceutical dosage forms through the small intestine.

  1986cited by this paper
• Clinical Pharmacokinetics: Concepts and applications.

  1983cited by this paper
• The Enzyme Defect in Fabry's Disease

  1970cited by this paper
• Fabry's Disease: Alpha-Galactosidase Deficiency

  1970cited by this paper

• A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease

  2024cites this paper
• A review and recommendations for oral chaperone therapy in adult patients with Fabry disease

  2024cites this paper
• Pharmacists' knowledge of drug food administration and their appropriate patient counseling a cross-sectional study from Palestine

  2023cites this paper
• Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice

  2021cites this paper
• [Chaperone molecules: The example of Fabry disease].

  2021cites this paper
• The Influence of Foods and Beverages on Polyethylene Glycol Marker Detection in Urine

  2019cites this paper
• Strong increase of leukocyte apha‐galactosidase A activity in two male patients with Fabry disease following oral chaperone therapy

  2019cites this paper
• Migalastat: A Review in Fabry Disease

  2019cites this paper
• Migalastat for the treatment of Fabry disease

  2018cites this paper
• Migalastat: First Global Approval

  2016cites this paper
• Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

  2015cites this paper